Abstract
Purpose :
To assess visual outcomes of pts with nAMD by BL features of CNV during the first year (BL–week (wk) 52) of VIEW studies.
Methods :
Pts with nAMD (n=2457) were randomized to receive one of the following treatments from BL to wk 52: 0.5 mg intravitreal ranibizumab q4 wks, 2 mg intravitreal aflibercept injection (IAI) q4 wks, 0.5 mg IAI q4 wks, or 2 mg IAI q8 wks after 3 monthly injections. Using Kaplan-Meier methodology, cumulative incidences of the first sustained (≥2 consecutive occurrences) gain of ≥15 letters and loss of >5 letters were assessed in pooled treatment groups in an integrated analysis of the VIEW studies by quartiles (Q) of BL CNV area (Q1: <3.12, Q2: ≥3.12-<6.00, Q3: ≥6.00-<10.08, Q4: ≥10.08 mm2) and CNV type (occult, minimally classic [MC], predominantly classic [PC]).
Results :
There were 596, 603, 598, and 602 pts in Q1–Q4, respectively. By wk 52, corresponding cumulative incidences of the first sustained gain of ≥15 letters were 46.5%, 39.2%, 32.1%, and 31.8%, respectively. Similarly, cumulative incidences of the first sustained loss of >5 letters were 8.9%, 12.2%, 21.5%, and 22.0% in Q1–Q4, respectively. There were 924, 837, 629 pts with occult, MC and PC lesions, respectively. Corresponding cumulative incidences of the first sustained gain of >15 letters were 32.3%, 37.5%, and 45.5%. Similarly, cumulative incidences of the first sustained loss of >5 letters were 14.3%, 17.4%, and 17.4%, respectively. Relative risks of the first sustained gain of ≥15 letters and loss of >5 letters from baseline by baseline CNV size and type are shown in Table.
Conclusions :
These data suggest that, with increasing BL CNV area, cumulative incidence of the first sustained ≥15 letters gain decreased and cumulative incidence of >5 letters loss increased in a non-linear manner for both visual acuity outcomes. The lowest cumulative incidence of the first sustained >15 letters gain and >5 letters loss was seen amongst pts with occult lesions.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.